About GlycoPolymer Technology
Aequus' GlycoPolymer technology allows drug developers to create novel biopharmaceuticals that require less frequent injections (i.e., monthly rather than daily) due to their improved pharmacokinetic properties. The technology genetically ligates an external amino acid domain to a therapeutic protein or peptide candidate that results in additional N-linked glycosylation. The presence of additional, appropriately-formed, N-linked glycan chains has been demonstrated to have a beneficial effect on plasma half-life. The modular GlycoPolymer technology provides a more technically straightforward and predictable approach to extend the plasma half-life of a protein compared to the previously utilized method of engineering novel glycosylation sites internal to the therapeutic protein sequence.
AQB-101 is a novel GlycoPolymer-based glycoprotein that possesses granulocyte colony stimulating factor-like activity. AQB-101 was created by Aequus to demonstrate the utility of the GlycoPolymer technology platform, as well as to create a novel colony stimulating factor therapeutic agent to compete in this significant biopharmaceutical marketplace.
About Aequus BioPharma, Inc.
Bainbridge Island WA
, Aequus is a biopharmaceutical company committed to streamlining the development and manufacture of novel and 'follow-on' therapeutic protein drugs. Aequus is a majority owned subsidiary of Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC).
About Cell Therapeutics, Inc.
, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.
This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of the drug candidate AQB-101 include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with AQB-101 in particular, including, without limitation, the potential failure of AQB-101 to create a novel
colony stimulating factor
therapeutic agent, that Aequus's application of modular GlycoPolymer technology to biologically active proteins and peptides may not facilitate the development of therapeutic protein-based drugs that require less frequent dosing and offer improved patient convenience, that AQB-101 may not demonstrate the utility of the GlycoPolymer technology platform, CTI's and Aequus's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's and Aequus's product candidates, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.